Cardiometabolic Disorders News

Bayer announced positive top-line results for the FINEARTS-HF trial of finerenone, in which the drug reduced risk for cardiovascular death and heart failure events in patients with HF with preserved or mildly reduced ejection fraction.

The number of monthly prescription fills for semaglutide increased by 442% from 2021 to 2023, according to a research letter published in JAMA Health Forum.

The FDA granted breakthrough device designation for an endoscopic procedure that resurfaces the duodenum lining to allow for weight maintenance after discontinuation of a GLP-1 receptor agonist, according to an industry press release.

Using the American Heart Association’s new PREVENT risk calculator would mean reducing eligibility for statin and/or antihypertensive therapy by approximately 16 million U.S. adults, researchers reported in JAMA.

The FDA is warning providers and patients that dosing errors with compounded injectable semaglutide may be leading to adverse events, according to a press release.

In October 2023, the American Heart Association unveiled the term cardiovascular-kidney-metabolic syndrome to reflect the connection between metabolic and renal conditions associated with risk for heart disease.

Women with polycystic ovary syndrome and high androgen levels may have a higher risk for liver disease than those with PCOS and normal androgen levels, according to an analysis of UK Biobank data.

In a single-center cohort of patients with heart failure and obesity, weight-loss surgery led to improved clinical outcomes including reduced BMI and HbA1c and less reliance on diuretics, researchers reported.

People with excess adiposity in young adulthood were more likely to have adverse cardiac structure and function later in life compared with people without it, researchers reported in the European Heart Journal.

GLP-1 receptor agonist use in diabetes and obesity has soared, and indications are now expanding into liver diseases, specifically metabolic dysfunction-associated steatohepatitis. However, the jury is still out on its benefits.